- Home
- UBX vs SRZN Comparison
UBX vs SRZN Comparison
Compare UBX & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBX
- SRZN
- Stock Information
- Founded
- UBX 2009
- SRZN 2015
- Country
- UBX United States
- SRZN United States
- Employees
- UBX N/A
- SRZN N/A
- Industry
- UBX Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- UBX Health Care
- SRZN Health Care
- Exchange
- UBX Nasdaq
- SRZN Nasdaq
- Market Cap
- UBX 36.9M
- SRZN 38.1M
- IPO Year
- UBX 2018
- SRZN N/A
- Fundamental
- Price
- UBX $1.72
- SRZN $11.35
- Analyst Decision
- UBX Strong Buy
- SRZN Strong Buy
- Analyst Count
- UBX 3
- SRZN 2
- Target Price
- UBX $7.33
- SRZN $38.50
- AVG Volume (30 Days)
- UBX 129.4K
- SRZN 15.8K
- Earning Date
- UBX 03-07-2025
- SRZN 05-07-2025
- Dividend Yield
- UBX N/A
- SRZN N/A
- EPS Growth
- UBX N/A
- SRZN N/A
- EPS
- UBX N/A
- SRZN N/A
- Revenue
- UBX N/A
- SRZN $10,000,000.00
- Revenue This Year
- UBX N/A
- SRZN N/A
- Revenue Next Year
- UBX N/A
- SRZN N/A
- P/E Ratio
- UBX N/A
- SRZN N/A
- Revenue Growth
- UBX N/A
- SRZN N/A
- 52 Week Low
- UBX $0.94
- SRZN $6.00
- 52 Week High
- UBX $3.10
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- UBX 46.69
- SRZN 49.35
- Support Level
- UBX $1.53
- SRZN $11.11
- Resistance Level
- UBX $1.76
- SRZN $12.00
- Average True Range (ATR)
- UBX 0.20
- SRZN 0.71
- MACD
- UBX -0.02
- SRZN 0.05
- Stochastic Oscillator
- UBX 34.99
- SRZN 53.61
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).